RUNX2 is overexpressed in melanoma cells and mediates their migration and invasion

Boregowda, Rajeev K.; Olabisi, Oyenike O.; Abushahba, Walid; Jeong, Byeong‐Seon; Haenssen, Keneshia K.; Chen, Wenjin; Chekmareva, Marina; Lasfar, Ahmed; Foran, David J.; Goydos, James S.; Cohen‐Solal, Karine

doi:10.1016/j.canlet.2014.03.011

Cited by 42 publications

(45 citation statements)

References 53 publications

(70 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Each Runx protein has a unique function: Runx1 is essential for hematopoiesis, Runx3 is important for nerve cell development, and Runx2 is a key regulator of bone development. A Runx2 -deficient mice model showed a complete lack of bone formation [10,14,17]. Recent studies have shown that Runx2 was associated with tumor cell invasion and metastasis.…”

Section: Discussionmentioning

confidence: 99%

“…Recent studies have shown that Runx2 was associated with tumor cell invasion and metastasis. Boregowda and colleagues demonstrated that a reduction in Runx2 activity led to decreased growth, migration, and invasion in melanoma cells [14]. Baniwal et al found that Runx2 promoted invasion and metastasis to bone in prostate cancer cells [23].…”

Section: Discussionmentioning

confidence: 99%

“…Runx2 is also important in skeletal development [12,13]. Recent studies have found that Runx2 is overexpressed in cancer cells, enhancing their migration and invasion [10,14,15,16,17,18]. …”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

The Expression and Functional Significance of Runx2 in Hepatocellular Carcinoma: Its Role in Vasculogenic Mimicry and Epithelial–Mesenchymal Transition

Cao

Sun

Zhao

et al. 2017

IJMS

View full text Add to dashboard Cite

The transcription factor Runx2 has been reported to promote epithelial-mesenchymal transition (EMT) in many tumors. Vasculogenic mimicry (VM) is described as the mimicry of endothelial cells by tumor cells to form microvascular tubes in aggressive tumors. Galectin-3 has been reported to regulate cell invasion, migration, and VM formation; it could be regulated by Runx2. However, the relationship between Runx2, Galectin-3, EMT, and VM has not been studied in hepatocellular carcinoma (HCC). We examined Runx2 expression in 89 human HCC samples and found Runx2 expression was associated with VM. Clinical-pathological data analysis revealed that Runx2 expression was associated with a shorter survival period. Overexpression of Runx2 promoted EMT and enhanced cell migration, invasion, and VM formation in HepG2 cells. Conversely, the downregulation of Runx2 inhibited EMT and reduced cell invasion, migration, and VM formation in SMMC7721. Galectin-3 expression declined following the downregulation of Runx2 in HepG2 cells, and increased in SMMC7721 cells after Runx2 knockdown. We consistently demonstrated that the downregulation of LGALS3 in HepG2-Runx2 cells reduced cell migration; invasion and VM formation; while upregulation of LGALS3 in SMMC7721-shRunx2 cells enhanced cell migration, invasion, and VM formation. The results indicate that Runx2 could promote EMT and VM formation in HCC and Galectin-3 might have some function in this process.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The Expression and Functional Significance of Runx2 in Hepatocellular Carcinoma: Its Role in Vasculogenic Mimicry and Epithelial–Mesenchymal Transition

Cao

Sun

Zhao

et al. 2017

IJMS

View full text Add to dashboard Cite

show abstract

“…Factors that are crucial during embryogenesis are often hijacked during cancer progression, and RUNX2 is not an exception. RUNX2 is increasingly recognized in cancer biology for its oncogenic properties and a large number of articles link the deregulation of RUNX2 expression with progression and metastasization of different types of epithelial tumors (1,(3)(4)(5)(6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18). Regulation of RUNX2 may occur at multiple levels and through multiple signaling pathways.…”

Section: Introductionmentioning

confidence: 99%

Histone Deacetylase Inhibitors Repress Tumoral Expression of the Proinvasive Factor RUNX2

Sancisi¹,

Gandolfi²,

Ambrosetti

et al. 2015

Cancer Research

View full text Add to dashboard Cite

Aberrant reactivation of embryonic pathways occurs commonly in cancer. The transcription factor RUNX2 plays a fundamental role during embryogenesis and is aberrantly reactivated during progression and metastasization of different types of human tumors. In this study, we attempted to dissect the molecular mechanisms governing RUNX2 expression and its aberrant reactivation. We identified a new regulatory enhancer element, located within the RUNX2 gene, which is responsible for the activation of the RUNX2 promoter and for the regulation of its expression in cancer cells. Furthermore, we have shown that treatment with the anticancer compounds histone deacetylase inhibitor (HDACi) results in a profound inhibition of RUNX2 expression, which is determined by the disruption of the transcription-activating complex on the identified enhancer. These data envisage a possible targeting strategy to counteract the oncongenic function of RUNX2 in cancer cells and provide evidence that the cytotoxic activity of HDACi in cancer is not only dependent on the reactivation of silenced oncosuppressors but also on the repression of oncogenic factors that are necessary for survival and progression.Cancer Res; 75(9); 1868-82. Ó2015 AACR.

show abstract

“…Cholecalciferol, precursor to active vitamin D3, repressed melanoma cell migration by reducing the transcriptional activity of RUNX2, demonstrating another link tying vitamin D3 to carcinoma metastasis. [45] Another class of compounds that tumor cells manufacture are matrix metalloproteinases, notably MMP-9 and MMP-13, which enhance their growth and promote metastasis. This production is accelerated when cells are exposed to TNF-α.…”

Section: Vitamin D As a Cancer Suppressormentioning

confidence: 99%

Immunological Role of Vitamin D in Skin Diseases and Carcinoma

Yuan¹,

Madu²,

Lu³

2017

Oncomedicine

View full text Add to dashboard Cite

Growing evidence attests to the vital role vitamin D plays in the dynamics of the immune system. Active 1,25(OH)2D3 binds to the vitamin D receptor (VDR) to form a ligand-activated receptor complex able to control transcription in the nucleus. We examined the various mechanisms through which vitamin D3 alters and enhances immune responses in a variety of skin conditions, as well as the pathways it activates to inhibit the progression of tumors and carcinomas. The hormone primarily elicits a change as either an inflammation modulator or cancer suppressor. Also addressed are current advancements in vitamin D treatment methods through the development of novel analogs.

show abstract

RUNX2 is overexpressed in melanoma cells and mediates their migration and invasion

Cited by 42 publications

References 53 publications

The Expression and Functional Significance of Runx2 in Hepatocellular Carcinoma: Its Role in Vasculogenic Mimicry and Epithelial–Mesenchymal Transition

The Expression and Functional Significance of Runx2 in Hepatocellular Carcinoma: Its Role in Vasculogenic Mimicry and Epithelial–Mesenchymal Transition

Histone Deacetylase Inhibitors Repress Tumoral Expression of the Proinvasive Factor RUNX2

Immunological Role of Vitamin D in Skin Diseases and Carcinoma

Contact Info

Product

Resources

About